RELX PLC

RELX PLC — Business Economics

Ticker: RELX | Primary listing: LSE (GBP); ADR on NYSE (USD)

RELX is one of the highest-quality compounding machines in global equities — a data and analytics business disguised by its legacy description as a "publisher." The economic engine is simple and powerful: assemble proprietary datasets that are prohibitively expensive to replicate, embed analytical tools into customers' daily workflows, and charge recurring subscriptions that grow with usage. Over 85% of revenue is now electronic, and roughly three-quarters is recurring or subscription-based.

How it makes money. RELX operates four segments, each with distinct economics. The most recent full-year data is FY2024 (year ended December 31, 2024), sourced from the 20-F filed February 2025.

The engine is strengthening, not weakening. The critical trend is the ongoing mix shift toward Risk & Business Analytics, which now accounts for over 40% of revenue and carries the highest margins and fastest growth. This segment benefits from structural tailwinds — rising digital fraud, regulatory KYC/AML requirements, and insurance carriers needing better predictive analytics. Each new data source integrated into the platform increases its value to customers (a flywheel effect). The segment has compounded organic growth at ~8-10% for a decade with no sign of deceleration.

Win-win dynamics. RELX's model genuinely creates value for counterparties. Insurers price risk more accurately. Researchers access the literature more efficiently. Lawyers find precedent faster. The one area of legitimate tension is academic publishing — Elsevier's subscription pricing and the open-access movement create friction with universities and funding bodies. This is a real but manageable structural risk; Elsevier has been transitioning to hybrid/open-access models, and its dominance in research tools (Scopus, SciVal) provides resilience beyond pure journal access.

No signs of deterioration. Every segment is growing organically. Customer retention rates across the platform are consistently above 90%. The transition from print to digital is essentially complete, removing a historic drag. Capital expenditure is low relative to revenue (~7-8%), and free cash flow conversion from adjusted operating profit is consistently above 90%.

Key metrics to track: (1) organic revenue growth by segment — particularly Risk Analytics staying above high-single-digits; (2) adjusted operating profit margin expansion as mix continues shifting toward higher-margin segments; (3) electronic revenue as a percentage of total; (4) free cash flow conversion ratio. If Risk Analytics organic growth were to fall below 5% or STM margins contracted sharply due to open-access disruption, the thesis would need re-examination.

RELX PLC — Market Overview

RELX operates across four professional information and analytics markets that collectively offer a powerful secular tailwind — the digitisation of decision-making in risk, science, and law. The company's mix has meaningfully shifted: Risk Analytics now contributes ~40% of group revenue (up from ~25% a decade ago), and this segment serves the fastest-expanding end-market of the four.

Risk Analytics (~40% of revenue) addresses insurance underwriting, fraud detection, identity verification, and regulatory compliance. The addressable market here is vast — broadly $30–40 billion globally — and expanding at high-single-digit rates as institutions layer more third-party data into automated decision workflows. Regulatory tightening (KYC/AML, insurance pricing accuracy) and rising fraud losses create non-discretionary demand. RELX's LexisNexis Risk Solutions is the dominant provider, with proprietary databases (HPCC, CLUE, ThreatMetrix) that create formidable data network effects. The closest competitor of scale is Verisk, but the two largely operate in adjacent niches rather than head-to-head.

Scientific, Technical & Medical (~33%) is a mature market growing low-single-digits. Academic publishing is a consolidated oligopoly — Elsevier, Springer Nature, Wiley, and a few others control the bulk of high-impact journals. Open access is a structural headwind to legacy subscription models but has been slower to erode economics than feared; Elsevier has pivoted toward transformative agreements and analytics tools (SciVal, ScienceDirect, Scopus) that add stickiness. The real growth engine within STM is analytics, not publishing.

Legal (~18%) is essentially a global duopoly between LexisNexis and Thomson Reuters' Westlaw. This market grows mid-single-digits, driven by legal analytics, AI-assisted research, and expansion into corporate/regulatory compliance. Neither player faces meaningful disruption risk; switching costs are extreme.

Exhibitions (~9%) is the weakest market — fragmented, cyclical, and capital-light but lower quality. RELX has been de-emphasising this segment over time.

The critical insight: RELX's portfolio is deliberately migrating toward analytics and away from static content. Analytics revenue now exceeds 40% of the group and carries higher growth, margins, and switching costs than legacy publishing. The market tailwind is structural — every segment benefits from the shift toward data-driven professional decision-making — and the competitive landscape is consolidated in RELX's favour across three of its four segments.

RELX PLC — Moat / Competitive Advantages

RELX possesses one of the widest and most durable moats in the global information services sector, anchored by proprietary data that compounds over time and switching costs so deep they are effectively permanent across all four segments. The moat is actively widening as the business shifts from static content delivery toward embedded analytics and AI-driven decision tools.

Data / Information Advantage (Primary Moat). This is the core of the franchise. LexisNexis Risk Solutions sits atop ~80 billion public and proprietary records for identity verification, fraud detection, and insurance underwriting. This dataset improves with every transaction — more contributors yield better models, which attract more users — creating a flywheel. Elsevier's Scopus indexes ~90 million records and ~27,000 journals; decades of curated metadata cannot be replicated. This advantage is strengthening: RELX invested over £1.7bn in technology capex in FY2025 (up from ~£1.4bn five years prior), increasingly layering AI/ML models atop proprietary data, widening the gap with competitors who lack the underlying datasets.

Switching Costs / Cultural Embeddedness. LexisNexis is the default research tool for the legal profession — trained in law school, integrated into firm workflows. Elsevier's ScienceDirect is institutionally embedded in academic research ("publish or perish" in high-impact Elsevier journals). Risk Analytics tools are hard-coded into insurance underwriting engines, bank KYC/AML compliance systems, and government identity verification processes via API integration. Ripping these out would mean regulatory risk, retraining costs, and operational disruption — customers don't leave.

Toll Bridge / Chokepoint. In regulated industries (banking, insurance, government), identity verification and fraud screening are mandatory. LexisNexis Risk Solutions is the dominant provider in the US — it is not optional, it is infrastructure. Similarly, Elsevier controls many top-tier journals; researchers have no substitute for publishing in Cell, The Lancet, or Journal of Financial Economics.

Economies of Scale. Near-zero marginal cost of serving an additional subscriber across a fixed-cost content and data infrastructure. RELX's adjusted operating margins (~33% group-wide, ~39% in Risk Analytics as of FY2025) reflect this leverage and are difficult for smaller competitors to match.

Moat Trajectory: Widening. The shift from content → analytics → embedded decision tools increases stickiness with each step. Risk Analytics (now ~40% of group revenue) is the fastest-growing segment and has the strongest moat dynamics. AI capabilities built on proprietary data are creating a second derivative of competitive advantage that pure-content or pure-technology competitors cannot replicate — they lack either the data or the domain embedding.

RELX PLC — Financial Strength

RELX is a financial fortress — asset-light, cash-generative, and conservatively leveraged, with returns on capital that comfortably exceed the cost of capital through every environment.

Returns on capital are elite. Adjusted ROIC on tangible assets is exceptionally high given the near-zero marginal cost of delivering digital content and analytics. Even on a total invested capital basis (including ~£10bn of acquisition goodwill), ROIC sits in the mid-teens, roughly double a ~7-8% WACC. Adjusted operating margins have expanded steadily from ~31% (FY2020) to ~35% (FY2024, revenue £9.35bn), driven by the growing mix of higher-margin Risk Analytics and inherent operating leverage in digital platforms.

Debt is a tool, not a crutch. Net debt/EBITDA of ~2.0x is conservative for a business of this quality and stability. Interest cover runs ~8-10x. Maturities are well-laddered across long-dated investment-grade bonds (BBB+/Baa1). The subscription-driven revenue base means cash flows barely flinch in downturns — RELX grew revenue through COVID and the 2008-09 crisis with minimal disruption. This business could service its debt through any plausible scenario.

Earnings quality is outstanding. FCF conversion consistently runs 90–100% of adjusted net income. Capex is ~5% of revenue — the bulk of investment flows through the P&L as product development expense. Working capital is structurally favorable: customers pay subscriptions upfront, creating a negative working capital cycle. Receivables growth tracks revenue with no concerning divergence.

No hidden liabilities. Goodwill is substantial (~£10bn) but reflects real, revenue-producing acquisitions in data assets (LexisNexis Risk Solutions, ThreatMetrix, etc.) that are performing well — no impairment risk is evident. Pension obligations are modest and funded. No customer concentration risk exists — the base spans millions of professionals and institutions globally. Ernst & Young has provided clean audits continuously with no auditor changes or qualifications. (Most recent data: FY2024 annual results; FY2025 20-F filed Feb 2026 but financial details not extracted.)

RELX PLC — Runway for Reinvestment

RELX has a long reinvestment runway, but its asset-light model means the business generates far more cash than it can redeploy at high incremental returns — a quality problem that limits compounding velocity but not durability.

Returns on capital are exceptional and expanding. ROIC (including goodwill from decades of acquisitions) runs at ~20–25%, driven by the shift toward Risk Analytics (now ~40% of revenue, highest margins). Stripping out goodwill, returns on tangible capital exceed 100% — the business requires almost no physical assets. The implied organic growth math checks out cleanly: RELX reinvests roughly 25–30% of NOPAT (through capitalized technology development of ~£600m+ annually) at 25%+ incremental returns, producing ~7–8% organic growth — exactly what it has delivered consistently.

Capital deployment is disciplined but constrained. RELX systematically acquires bolt-on data assets (typically £400m–£1bn annually) that feed its analytics engines. These have been value-accretive — Risk Analytics' organic growth acceleration from ~7% to 10%+ reflects both internal R&D and acquired data sets compounding together. However, the business simply cannot absorb all its FCF at these returns. The surplus — roughly 70–75% of FCF — gets returned to shareholders via growing dividends and buybacks.

AI extends the runway. The most important reinvestment avenue isn't acquisitions — it's embedding AI into existing data workflows across all four segments. This is high-ROIC organic spend that deepens switching costs, improves product utility, and expands addressable markets (new use cases in fraud detection, clinical trial optimization, legal analytics). The TAM for data-driven decision tools is expanding, not contracting.

The limitation: RELX cannot meaningfully accelerate capital deployment without overpaying for acquisitions. It is a compounder that returns excess cash rather than a reinvestment machine that redeploys everything internally. For a ~7–8% organic grower at 25%+ ROIC, this is a minor constraint — the quality of growth matters more than the quantity of reinvestment.

RELX PLC — Peer Comparison

RELX is the strongest all-round compounder in its peer group, gaining share across its highest-value segments while trading at a roughly in-line multiple.

RELX competes across four distinct arenas, each with different peer sets. In Risk Analytics (its largest and fastest-growing segment at ~40% of profit), LexisNexis Risk Solutions competes with Verisk, TransUnion, and Equifax — but its unique contributory data assets (the HPCC platform, >100B public records) have driven market-share gains for a decade. In Legal, LexisNexis sits in a stable duopoly with Thomson Reuters' Westlaw; both are investing aggressively in GenAI-powered tools, and neither is clearly pulling away. In STM, Elsevier is the dominant publisher (>15% of global articles) versus Springer Nature, Wiley, and Taylor & Francis — and has defended share through the open-access transition by layering analytics tools (SciVal, Scopus, Pure). Exhibitions (RX) competes with Informa but is small and strategically secondary.

The closest whole-company comparables are Wolters Kluwer (professional information, legal, health, tax) and Thomson Reuters (legal, tax, news). Verisk is the best pure-play comp for the Risk segment.

RELX is gaining share driven by three factors: (1) the compounding network effects of its risk-data assets, (2) cross-selling analytics products into its embedded customer base, and (3) disciplined reinvestment of ~10% of revenue into technology and content. Organic growth has accelerated from ~4% (2016-18) to ~7-8% (2023-24), a trajectory unmatched in the peer group for a business of its scale. Its margin is slightly below Thomson Reuters and well below Verisk, but RELX's diversification and superior growth balance give it arguably the best risk-adjusted profile. Valuation is rich in absolute terms (~33x forward earnings) but reasonable relative to the peer group's 29x–43x range, given RELX's combination of growth, margin expansion, and capital-light cash generation.

RELX PLC — Management & Shareholder Orientation

RELX's management is exceptionally aligned with long-term shareholders, demonstrated through 15+ years of disciplined capital allocation rather than ownership stakes alone.

Erik Engstrom has served as CEO since 2009 — an unusually long and successful tenure that has overseen RELX's transformation from a legacy publisher into a data-analytics compounder. His leadership style is low-profile and operationally disciplined, eschewing large transformative M&A in favor of steady organic investment and bolt-on acquisitions. This is the kind of CEO temperament long-term investors want: boring, compounding, and patient.

Skin in the game is moderate in absolute terms — typical for a £70bn+ FTSE 100 company where no single insider can hold a meaningful percentage. Executive compensation, however, is well-structured: the LTIP uses adjusted EPS growth, ROIC, and relative TSR over a three-year performance period with a mandatory two-year post-vesting holding period. These are precisely the metrics that drive long-term per-share value.

Capital return is the strongest proof of alignment. RELX has reduced its share count from over 2.1 billion to approximately 1.82 billion through consistent buybacks of ~£800m–£1bn annually, while simultaneously raising the dividend every year for over two decades. This is not a company hoarding cash or making empire-building acquisitions — it returns virtually all free cash flow to shareholders in a tax-efficient mix.

Governance follows the UK Corporate Governance Code with a clear majority of independent non-executive directors. There are no related-party transactions of concern and no regulatory actions against leadership. The board has been refreshed periodically, and succession planning appears orderly. The shareholder register is dominated by high-quality institutional holders (BlackRock, Vanguard, Capital Group) with no activist involvement — a sign the market broadly trusts management's direction. Insider transactions follow the typical FTSE pattern of periodic post-vesting sales rather than aggressive dumping, and there is no pledge concern.

RELX PLC — Management Competence & Ethics

Erik Engstrom's tenure as CEO (since 2009) ranks among the finest corporate transformations in the information-services industry — pivoting RELX from a legacy print publisher into a technology-driven data and analytics business while compounding shareholder returns at a high-teens annualised rate.

Capital allocation is textbook disciplined. RELX deploys a clear framework: invest organically in technology platforms first, make bolt-on acquisitions for data assets second, return surplus cash third. Acquisitions have been overwhelmingly small-to-mid-size and strategically coherent (ThreatMetrix ~$840M in 2018, Emailage in 2020, numerous smaller data-asset tuck-ins). There are no major write-downs or value-destroying deals on the record. Goodwill impairments have been negligible. Share buybacks have been substantial and consistent — roughly £1B+ annually in recent years — funded from strong free cash flow rather than leverage. Dividends have grown ~7-8% per annum for over a decade consecutively. ROIC has remained consistently in the high-teens to low-20s percent range, well above cost of capital.

Execution against stated goals has been excellent. Management has guided toward steady underlying revenue growth (mid-single digits), margin expansion, and increasing electronic/analytics mix — and delivered on all three for over a decade. Underlying revenue growth has accelerated from ~3% in the early Engstrom years to 6-8% more recently, driven by Risk Analytics. Adjusted operating margins have expanded steadily. The company says what it will do and does it, without drama or resets.

Transparency is strong but not flawless. Financial disclosure is detailed and segmental reporting is clear. There are no financial restatements, auditor disagreements, or fraud allegations in the company's history. Two ethical considerations warrant mention: (1) Elsevier's academic publishing pricing has drawn sustained criticism from the scientific community and some governments, though this is a structural industry debate rather than a management integrity issue; (2) LexisNexis Risk Solutions has faced scrutiny over data privacy practices and law enforcement contracts (including ICE), raising reputational questions that management has navigated without material financial impact. No material pending litigation threatens the business.

RELX PLC — Valuation

Financial data as of FY2025 (December 31, 2025). Stock price as of August 4, 2026.

RELX trades at a reasonable-to-attractive multiple for a business of its quality, sitting ~30% below its 52-week high. The current trailing P/E of ~22x and 5% FCF yield price in roughly 6–7% annual earnings growth — well below the ~9–10% the company has actually delivered for over a decade. The stock is not screaming cheap, but for a compounder of this caliber, the current entry point is the best seen in several years.

What's embedded in the price. At EUR 54.58B market cap against ~EUR 2.4B in net income (GBP figures converted at ~1.18 EUR/GBP), the market is paying 22.5x trailing earnings. A reverse-DCF at 9% discount rate implies the market is pricing in roughly 6% long-term earnings growth. RELX has compounded EPS at ~10% annually (2022–2025: £0.85 → £1.13), driven by 7–8% organic revenue growth, steady margin expansion, and ~2% per year share count reduction via buybacks. The gap between priced-in and delivered growth creates the investment opportunity.

Management credibility. RELX avoids explicit numeric guidance but consistently signals continued improvement in organic revenue growth and adjusted operating margins. Under CEO Erik Engstrom's tenure, the company transformed from a legacy publisher into a data analytics powerhouse — with Risk Analytics now the dominant segment. The management team has an essentially unblemished delivery record over the last decade. I treat their forward commentary as highly credible.

Liquidation value is irrelevant here. Tangible book value is negative (−£8.6B). Goodwill and intangibles from decades of acquisitions dominate the balance sheet. Net debt/EBITDA of 1.9x is very comfortable. The franchise value — proprietary data sets, embedded workflows, and 90%+ renewal rates — is the real asset, and it cannot be replicated.

Probability-weighted expected market cap: ~EUR 88B (61% upside over 5 years, ~10% CAGR + ~2.3% dividend = ~12% total return). For a business with beta of 0.26 and near-zero cyclicality, that is an attractive risk-adjusted proposition. RELX is not obviously cheap — it rarely is — but the current pullback from EUR 45 to EUR 31 offers a better-than-normal entry point for a business that grinds upward with unusual consistency.

RELX PLC — Long-term Valuation

(Most recent data: FY2025, ending December 31, 2025)

RELX is a rare compounder where all three value-creation forces — reinvestment runway, returns on capital, and capital discipline — operate simultaneously and reinforce each other. A base case of 2.5–3× over 10 years is credible if the moat holds, with the current ~31% drawdown from highs improving entry odds.

Moat durability. The moat's centre of gravity has shifted to Risk Analytics (LexisNexis Risk Solutions), which exhibits genuine data network effects: more participants in its insurance claims databases (CLUE, A-PLUS) and identity verification networks make the product more accurate, attracting more participants. This flywheel is self-reinforcing — each dollar reinvested into data acquisition and analytics widens the moat further rather than suffering declining marginal returns. Legal (LexisNexis) is protected by extreme switching costs: law firms build decades of workflow, templates, and training around these tools. STM (Elsevier) faces the most visible long-term pressure from open access mandates, but the shift to transformative agreements has so far preserved economics. The moat likely holds for 15+ years at the core, with STM being the first segment to see gradual erosion.

Reinvestment quality is rising, not falling. Operating margins expanded from 26.9% (2022) to 31.1% (2025) as the business mix shifts toward higher-margin digital analytics. FCF conversion is excellent — £2.31B FCF on £2.98B operating income. Incremental margins on data analytics products are structurally high (near-zero marginal cost once the database is built), meaning each unit of growth is more profitable than the last. AI is a tailwind here: RELX's proprietary datasets are the raw material AI tools need, making these products more valuable, not less.

Capital return discipline is accelerating. Buybacks tripled from £500M (2022) to £1.5B (2025), reducing share count by 5% in three years. Combined with £1.18B in dividends, total shareholder returns of £2.68B in 2025 consumed 116% of FCF. Net debt/EBITDA sits at a comfortable 1.9×, leaving room for continued aggressive returns. This buyback cadence at current valuations (~21× trailing) is genuinely accretive.

10-year return math. Organic revenue growth of 5–7% (Risk Analytics at 8–10%, offset by slower STM/Legal), plus 50–100bps annual margin expansion, plus 3–4% buyback yield, implies EPS growth of 10–13% annually. At a flat 21× multiple, that yields ~2.5–3× in 10 years. Downside case at 18× (multiple compression from maturity) still delivers ~2× — a floor set by the defensive, recurring cash flows. Upside to 3.5× if AI monetisation drives a rerating.

Competitive relevance under adversity. Inverting the question: how would RELX fail? It would require simultaneous regulatory restrictions on data collection (killing Risk Analytics), AI-native competitors displacing embedded legal workflows, and open access collapsing Elsevier's margins — all at once. Each is individually unlikely within a decade; collectively, the probability is negligible. The 0.26 beta reflects this structural resilience.

Thesis-breaking signals to monitor:

• Risk Analytics organic growth below 5% for two consecutive years
• Group operating margins declining (not flattening — declining) for two years
• Major regulatory action (CFPB or equivalent) forcing open data sharing that undermines proprietary databases
• Net revenue retention in subscription products falling below 95%

At EUR 31.26 (21.4× trailing, 16.4× forward), the price reflects reasonable — not demanding — expectations. For a 10-year compounder of this quality, the risk-reward is favourable.

RELX PLC — Risk Assessment

Most recent financial data: FY2025 (20-F filed February 19, 2026)

RELX faces no single risk likely to permanently impair the consolidated business. Its diversified, subscription-heavy model across four segments (Risk Analytics, STM, Legal, Exhibitions) means that even a severe disruption in one area would be absorbed by the others. The genuine risks are concentrated in two places — and only one could meaningfully damage long-term economics.

The critical risk is AI-driven disruption to STM publishing (Elsevier). If large language models commoditise access to scientific knowledge — synthesising findings without requiring article-level access — Elsevier's ~£3.5bn revenue base and 37%+ adjusted operating margins come under structural pressure. This is compounded by the Open Access movement and government mandates (Plan S, US OSTP policy) that erode the traditional subscription/paywall model. However, probability of catastrophic impairment is low (~15%). Elsevier is pivoting toward research analytics platforms (SciVal, Scopus, ScienceDirect integrations), and RELX is itself a sophisticated AI deployer. The segment would shrink, not disappear — researchers still need peer review, curation, and discovery infrastructure.

Data privacy regulation is a chronic constraint, not an existential one. Risk Analytics (LexisNexis Risk Solutions) — now the largest segment by revenue and profit — relies on vast consumer data assets (identity graphs, insurance claims, public records). GDPR, CCPA, and evolving US federal privacy legislation could restrict data collection or usage. The 20-F explicitly flags this as a principal risk. But RELX has navigated tightening privacy regimes for two decades; its compliance infrastructure is a competitive moat in itself, raising barriers for smaller entrants. The FTC consent orders on data practices require ongoing vigilance but reflect regulatory engagement, not adversarial action.

Financial risk is negligible. RELX carries ~£7–8bn net debt against ~£3.5bn adjusted operating profit and £2.5bn+ free cash flow. Net debt/EBITDA sits around 2x. Investment-grade ratings (A-/A3), well-laddered maturities (notes out to 2035), and a currency-diversified revenue base (~60% USD) make a liquidity or solvency event implausible. Currency translation creates reporting volatility but no economic risk to the underlying business.

Governance is clean. No key-person dependency — CEO Erik Engstrom led for over a decade before an orderly succession. No related-party concerns. Audited by EY. Diversified, independent board with strong UK governance standards. No fraud indicators.

Competitive displacement across LexisNexis Risk Solutions is the risk worth monitoring. If a hyperscaler (Google, Palantir) or well-funded fintech built a comparable identity/fraud analytics platform, it could pressure RELX's crown jewel. But the data moat — decades of accumulated proprietary records, network effects from thousands of contributing institutions — makes this the most defensible part of the business. No competitor has come close.

Net assessment: RELX's risk profile is among the most benign in the information-services sector. The STM disruption risk is real but contained to ~35% of group revenue and declining as Risk Analytics grows. No financial, governance, or competitive risk threatens permanent impairment of the consolidated enterprise.

RELX PLC — Final Verdict

Action: BUY. Build a position in tranches.

RELX is one of the highest-quality compounders in global equities — a toll-bridge business embedded in regulated professional workflows, earning 30%+ operating margins on a subscription base that barely flinched through COVID or any recession in two decades. At 21x trailing earnings and 16x forward — 31% below its 52-week high — the stock offers a rare entry into a business that almost never gets cheap.

The business case is unambiguous. Every research segment converged on the same conclusion: wide moat, widening further through AI and data network effects, elite capital allocation under Erik Engstrom, and near-zero probability of permanent impairment. EPS has compounded at ~10% annually (£0.85 → £1.13 over 2022-2025), driven by organic revenue growth, expanding margins, and accelerating buybacks (£500M → £1.5B annually). FCF conversion is exceptional — £2.3B of free cash flow on £2.1B of net income in 2025, a conversion rate above 110%.

The strongest argument against is that RELX is a known compounder trading at a "fair" multiple, not a mispriced asset — the market broadly understands this business. At 21x trailing, a reversion to 25-30x (its recent trading range) delivers strong returns, but if the multiple stays compressed, you're clipping ~12% annual returns (10% EPS growth + 2% dividend). That's excellent for this risk profile, but it's not a fat pitch. Additionally, AI-driven disruption to STM publishing (Elsevier) is a real structural headwind — though it's now less than 20% of group economics and shrinking as Risk Analytics dominates.

For existing holders: buy more. The drawdown from £45 to £31 changes nothing about the business and meaningfully improves forward returns. This is the kind of company you accumulate on weakness, not trade around.

Position sizing: two to three tranches. The quality warrants conviction, but the stock isn't at distressed levels. Initiate at current prices, add on any further weakness toward the 52-week low of €23, and build to a full position over the next quarter. This is not a "load the truck" moment — that would require a deeper valuation dislocation (15x trailing or below) for a business growing EPS at 10%.

Completeness check — areas for further work:

• Verify the forward P/E of 16.4x against consensus estimates (implies ~€1.90 EPS, or ~£1.60 — a 40%+ jump that may reflect currency or data artifacts)
• Track AI product adoption metrics in Risk Analytics (ThreatMetrix, ICIS Analytics) for signs of acceleration
• Monitor Elsevier open-access regulatory developments in EU and US for margin pressure
• Assess FX sensitivity given GBP reporting but EUR-denominated shares and significant USD revenue exposure